ID

31537

Description

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00427999

Lien

https://clinicaltrials.gov/show/NCT00427999

Mots-clés

Versions (1)
  1. 03/09/2018 03/09/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

3 septembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00427999

Anglais

Eligibility Prostate Cancer NCT00427999

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration).
Description

Prostate carcinoma | Disease Progression | Status post Hormone Therapy Primary | Male Castration | Medical Castration

Type de données

boolean

Alias
UMLS CUI [1]
C0600139
UMLS CUI [2]
C0242656
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0279025
UMLS CUI [3,3]
C0205225
UMLS CUI [4]
C0007347
UMLS CUI [5]
C1513054
patients must have increasing psa levels (within 3 months prior to enrollment) with at least two consecutively increasing psa levels.
Description

Serum Prostate Specific Antigen Increased Measurement Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1883014
UMLS CUI [1,2]
C0242485
UMLS CUI [1,3]
C1265611
psa value before inclusion must be at least 5 ng/ml
Description

Prostate specific antigen measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0201544
at least 18 years of age.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
at least capable of self care and up of at least 50% of waking hours (ecog performance status 0 - 2), adequate bone marrow function and lab results.
Description

Able to perform self care | Waking Hour Percentage | ECOG performance status | Bone Marrow function | Laboratory Results

Type de données

boolean

Alias
UMLS CUI [1]
C2712073
UMLS CUI [2,1]
C0442696
UMLS CUI [2,2]
C0439227
UMLS CUI [2,3]
C0439165
UMLS CUI [3]
C1520224
UMLS CUI [4,1]
C0005953
UMLS CUI [4,2]
C0031843
UMLS CUI [5]
C1254595
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
change of hormone therapy within 6 weeks prior inclusion
Description

Hormone Therapy Change

Type de données

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C0392747
prior chemotherapy
Description

Prior Chemotherapy

Type de données

boolean

Alias
UMLS CUI [1]
C1514457
therapy with imatinib, or therapy with other inhibitors of tyrosinkinase.
Description

imatinib | Tyrosine kinase inhibitor

Type de données

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2]
C1268567
second neoplasm diagnosed within 5 years before study start.
Description

Second Cancer

Type de données

boolean

Alias
UMLS CUI [1]
C0751623
patients who require therapy with warfarin
Description

Warfarin Required

Type de données

boolean

Alias
UMLS CUI [1,1]
C0043031
UMLS CUI [1,2]
C1514873
known diagnosis of hiv, hepatitis b, or hepatitis c infection.
Description

HIV Infection | Hepatitis B | Hepatitis C

Type de données

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
Description

Disease Severe Interferes with Diagnosis | Disease Unstable Interferes with Diagnosis | Disease Uncontrolled Interferes with Diagnosis | Disease Severe Interferes with Evaluation | Disease Unstable Interferes with Evaluation | Disease Uncontrolled Interferes with Evaluation | Heart failure Severe

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0011900
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0443343
UMLS CUI [2,3]
C0521102
UMLS CUI [2,4]
C0011900
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C0205318
UMLS CUI [3,3]
C0521102
UMLS CUI [3,4]
C0011900
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C0205082
UMLS CUI [4,3]
C0521102
UMLS CUI [4,4]
C1261322
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0443343
UMLS CUI [5,3]
C0521102
UMLS CUI [5,4]
C1261322
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C0205318
UMLS CUI [6,3]
C0521102
UMLS CUI [6,4]
C1261322
UMLS CUI [7,1]
C0018801
UMLS CUI [7,2]
C0205082
surgical therapy within 4 weeks before inclusion.
Description

Operative Surgical Procedures Recently

Type de données

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0332185
prior therapy with isotopes strontium or rhenium.
Description

Strontium Isotopes | rhenium

Type de données

boolean

Alias
UMLS CUI [1]
C0038468
UMLS CUI [2]
C0035419
radiation therapy to > 25% of bone marrow within 4 weeks before inclusion.
Description

Therapeutic radiology procedure Bone Marrow Percentage

Type de données

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
treatment with other experimental substances within 30 days before study start.
Description

Experimental drug

Type de données

boolean

Alias
UMLS CUI [1]
C0304229
other protocol-defined inclusion/exclusion criteria may apply
Description

Eligibility Criteria Study Protocol

Type de données

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT00427999

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Prostate carcinoma | Disease Progression | Status post Hormone Therapy Primary | Male Castration | Medical Castration
Item
histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration).
boolean
C0600139 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0279025 (UMLS CUI [3,2])
C0205225 (UMLS CUI [3,3])
C0007347 (UMLS CUI [4])
C1513054 (UMLS CUI [5])
Serum Prostate Specific Antigen Increased Measurement Quantity
Item
patients must have increasing psa levels (within 3 months prior to enrollment) with at least two consecutively increasing psa levels.
boolean
C1883014 (UMLS CUI [1,1])
C0242485 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Prostate specific antigen measurement
Item
psa value before inclusion must be at least 5 ng/ml
boolean
C0201544 (UMLS CUI [1])
Age
Item
at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Able to perform self care | Waking Hour Percentage | ECOG performance status | Bone Marrow function | Laboratory Results
Item
at least capable of self care and up of at least 50% of waking hours (ecog performance status 0 - 2), adequate bone marrow function and lab results.
boolean
C2712073 (UMLS CUI [1])
C0442696 (UMLS CUI [2,1])
C0439227 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
C1520224 (UMLS CUI [3])
C0005953 (UMLS CUI [4,1])
C0031843 (UMLS CUI [4,2])
C1254595 (UMLS CUI [5])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy Change
Item
change of hormone therapy within 6 weeks prior inclusion
boolean
C0279025 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
Prior Chemotherapy
Item
prior chemotherapy
boolean
C1514457 (UMLS CUI [1])
imatinib | Tyrosine kinase inhibitor
Item
therapy with imatinib, or therapy with other inhibitors of tyrosinkinase.
boolean
C0935989 (UMLS CUI [1])
C1268567 (UMLS CUI [2])
Second Cancer
Item
second neoplasm diagnosed within 5 years before study start.
boolean
C0751623 (UMLS CUI [1])
Warfarin Required
Item
patients who require therapy with warfarin
boolean
C0043031 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
HIV Infection | Hepatitis B | Hepatitis C
Item
known diagnosis of hiv, hepatitis b, or hepatitis c infection.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Disease Severe Interferes with Diagnosis | Disease Unstable Interferes with Diagnosis | Disease Uncontrolled Interferes with Diagnosis | Disease Severe Interferes with Evaluation | Disease Unstable Interferes with Evaluation | Disease Uncontrolled Interferes with Evaluation | Heart failure Severe
Item
severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
boolean
C0012634 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0011900 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0443343 (UMLS CUI [2,2])
C0521102 (UMLS CUI [2,3])
C0011900 (UMLS CUI [2,4])
C0012634 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0521102 (UMLS CUI [3,3])
C0011900 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0521102 (UMLS CUI [4,3])
C1261322 (UMLS CUI [4,4])
C0012634 (UMLS CUI [5,1])
C0443343 (UMLS CUI [5,2])
C0521102 (UMLS CUI [5,3])
C1261322 (UMLS CUI [5,4])
C0012634 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
C0521102 (UMLS CUI [6,3])
C1261322 (UMLS CUI [6,4])
C0018801 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
Operative Surgical Procedures Recently
Item
surgical therapy within 4 weeks before inclusion.
boolean
C0543467 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Strontium Isotopes | rhenium
Item
prior therapy with isotopes strontium or rhenium.
boolean
C0038468 (UMLS CUI [1])
C0035419 (UMLS CUI [2])
Therapeutic radiology procedure Bone Marrow Percentage
Item
radiation therapy to > 25% of bone marrow within 4 weeks before inclusion.
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Experimental drug
Item
treatment with other experimental substances within 30 days before study start.
boolean
C0304229 (UMLS CUI [1])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial